key: cord-1040257-0bray9wz
authors: Foster, Mitchell; Hill, Philip C.; Setiabudiawan, Todia Pediatama; Koeken, Valerie A. C. M.; Alisjahbana, Bachti; van Crevel, Reinout
title: BCG‐induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next‐generation vaccines
date: 2021-03-12
journal: Immunol Rev
DOI: 10.1111/imr.12965
sha: 7b0f52fa2d742d5e164aa29fe8d507978f1eedb7
doc_id: 1040257
cord_uid: 0bray9wz

The tuberculosis (TB) vaccine Bacillus Calmette‐Guérin (BCG) was introduced 100 years ago, but as it provides insufficient protection against TB disease, especially in adults, new vaccines are being developed and evaluated. The discovery that BCG protects humans from becoming infected with Mycobacterium tuberculosis (Mtb) and not just from progressing to TB disease provides justification for considering Mtb infection as an endpoint in vaccine trials. Such trials would require fewer participants than those with disease as an endpoint. In this review, we first define Mtb infection and disease phenotypes that can be used for mechanistic studies and/or endpoints for vaccine trials. Secondly, we review the evidence for BCG‐induced protection against Mtb infection from observational and BCG re‐vaccination studies, and discuss limitations and variation of this protection. Thirdly, we review possible underlying mechanisms for BCG efficacy against Mtb infection, including alternative T cell responses, antibody‐mediated protection, and innate immune mechanisms, with a specific focus on BCG‐induced trained immunity, which involves epigenetic and metabolic reprogramming of innate immune cells. Finally, we discuss the implications for further studies of BCG efficacy against Mtb infection, including for mechanistic research, and their relevance to the design and evaluation of new TB vaccines.

The discovery that BCG protects against Mtb infection (as defined by a positive interferonγ release assay (IGRA) result) and not just progression from Mtb infection to TB disease 2,3 has significant implications for basic and applied TB research. For basic research, it means that both innate and adaptive immune protective responses play a role in BCG protection. In addition to T cell-mediated responses, BCG-induced protection may involve humoral 4 and innate immune memory responses termed "trained immunity." 5 For applied research, it means that Mtb infection, not just disease, should be considered as an endpoint for TB vaccine trials. The advantage of this is that trials using Mtb infection as the primary endpoint can be much smaller than those focused on TB disease, potentially including only hundreds rather than many thousands of participants. 6 To facilitate research in this field, first we identify and justify five phenotypes of Mtb infection and disease, which are, or have potential to be, useful for basic and applied research, including vaccine trials. Secondly, we explore the evidence for BCG efficacy against Mtb infection using these phenotypes as a reference. As part of this, we explore evidence for limitations around BCG efficacy. Thirdly, we review the evidence around the possible mechanisms of BCG efficacy against Mtb infection phenotypes from animal and human studies.

And finally, we discuss the implications for future research studies and for the design and evaluation of new vaccines.

Historically, latent Mtb infection was regarded as a distinct phenotype whereby, in those who are exposed to, and infected by Mtb, and do not progress quickly to TB disease, the pathogen enters into a dormant state which either continues indefinitely or, with a new susceptibility in the host, reactivates to cause TB disease. 6 It is now thought that this is simplistic, and that Mtb is associated with a spectrum of phenotypes that can occur after exposure to the pathogen. 7, 8 To be fit for purpose to discuss BCG-induced protection, the range of phenotypes associated with Mtb infection need to be (or have the potential to be) measurable as potential endpoints for assessing efficacy and identifying mechanisms. We propose five such phenotypes, summarized in Table 1 .

The first phenotype is early clearance, which we have defined as the eradication of Mtb infection before an adaptive immune response develops. 9 Clear examples of individuals with evidence of early clearance include nursing students who never become tuberculin skin test (TST) positive in work environments with high Mtb transmission, 10 and sailors sharing a cabin for six months on a ship with others with pulmonary TB. 11 and chemical properties of saliva or mucous, or it may be through the innate immune system with or without involvement of other components of the immune system. We have defined early clearance of Mtb as persistent IGRA negativity over a three-month period after exposure. 3 It now appears that early clearance may be achieved with some Mtb exposures and not with others, depending on the presence or absence of associated variables, or it may occur in a smaller subset of individuals after every exposure that they may have. The latter "resisters" have been defined as having a repeatedly negative TST or IGRA over at least a two-year period after an initial exposure in a setting where ongoing exposure is likely, as reflected by ongoing conversion in other members of the same cohort. 12 One concern about the early clearance phenotype is whether a large proportion of such individuals are simply unexposed. To assist with this issue, several measures of exposure have been identified, including the characteristics and diagnostic findings of a symptomatic case in relation to their contacts (age, sex, sputum smear status, extent of disease on X-ray, duration and intensity of contact, and

Mtb strain) and aerosolization of the pathogen. These factors can be combined into an exposure score. 3 Another concern is whether the IGRA or TST are adequate to classify individuals as truly uninfected. Recently, Lu et al. 4 followed a cohort of 82 Ugandan case contacts of patients with TB who tested negative by IGRA and TST over an average of more than nine years of follow-up. There were no differences in antibodies to classic immunological targets between these "resisters" and controls who were positive by Mtb infection test. However, the "resisters" possessed IgM, class-switched IgG antibody responses, and non-IFNγ T cell responses to the Mtb proteins ESAT-6 and CFP-10. Of course, these individuals were subject to tuberculin injection by regular TST tests, which itself can induce an, albeit weak, immune response. There have also been no longitudinal studies to show whether such individuals are more likely than others to progress to TB disease.

The second phenotype is Mtb infection, whereby the pathogen has established an infection, but is not causing TB disease. These individuals are defined as positive by either one or both of TST or IGRA. Reviewed extensively elsewhere, 13 these two tests have similar performance characteristics, but there is significant discordance between them. TSTs are subject to a false-positive result, especially early in life, due to prior BCG vaccination. A TST can also cause boosting of subsequent TSTs. 14 IGRA tests are more likely to undergo reversion. 15 Both tests incur a drop in sensitivity in immunocompromised individuals.

Rather than considering these individuals as hosting Mtb in a dormant state, it is probably better to regard them as hosting an ongoing engagement between their immune system and the pathogen.

Within these individuals, multiple subpopulations of the pathogen exist in different states-some are actively engaging the immune system, whereas some are in a dormant state. Post mortem studies in humans with Mtb infection have demonstrated lesions that represent a subset of those seen in active TB disease, with variable recovery rates and physiological states of viable mycobacteria. 16 When the engagement of the immune system shifts in favour of the pathogen, these individuals may progress to develop disease. If this happens early, it is called progressive primary disease. If it occurs later, it is called re-activation disease.

A "subphenotype"-labelled "incipient TB" may prove to be distinguishable following advances in immune profiling and biomarker research. For example, the TB case-contact study platform, which we developed in The Gambia, 17 

The third phenotype is delayed clearance of Mtb infection. Interest in this phenotype has revived recently as the commonly held assumption of "lifelong infection" has been challenged. 21 However, the possibility of the existence of this phenotype has been recognized for many decades, as it was indicated from age-stratified prevalence studies. 22 at the level of the granuloma. 33 Gideon et al. showed that a particular combination of pro-and anti-inflammatory factors, rather than a strong Th1 response, are associated with sterilization of granulomas, offering hope that a biomarker of delayed clearance may be identified. 33 The animals with latent infection were followed for up to 601 days, and while many had at least one sterile granuloma, only approximately 5% had all of their evaluated granulomas sterile by the end of follow-up. Furthermore, systemic responses such as those measured by IGRA did not reliably reflect T cell responses at the level of the granuloma.

The fourth phenotype is subclinical TB disease. These individuals are completely asymptomatic but are positive on routine investigation for TB disease. Subclinical TB is identified most frequently in TB prevalence surveys and other active case-finding initiatives.

Often, these people will progress to symptomatic disease over time. PET/CT provide new insights into this phenotype. 34 There may be a case for including readouts from these investigations as part of the phenotype definition, although there may be some blurring of the boundary with Mtb infection and especially with the emerging incipient TB disease subphenotype described above.

Of note, ongoing changes on PET scan in individuals who have had curative TB treatment remain unexplained. 35 It is possible that they are "viable pathogen-free," purely localized immunological processes.

The fifth major phenotype is clinical TB disease. These individuals are symptomatic and are diagnosed with TB, often by a diagnostic test. If treated appropriately, over 90% will be cured and return to normal health. This article focuses on the first three phenotypes; the two disease phenotypes are not discussed further. 

The duration of BCG-induced protection is not known, although it has previously been regarded as limited to the first few years of life. 40 Recent studies suggest that BCG is effective against TB for at least 20 years when given at birth or school age. 41 

As mentioned above, it seems likely that particular circumstances, such as particularly high or prolonged exposure to Mtb, or increased host vulnerability may favour "immune evasion" by the pathogen over long-term host-mediated immune protection. In Indonesia, to assess BCG protection by level of Mtb exposure, we created one summary measure of exposure, calculating exposure risk scores predicted from a logistic regression of Mtb exposure variables (index case: sputum smear grade, cavities, extent of radiographic disease;

contacts: hours spent with, and sleeping proximity to, the case).

These exposure scores were compared against IGRA results. 3 We found an interaction between exposure and BCG vaccination in rela- 37% of children had a positive TST after exposure to a case for less than one month, with TST positivity rising steadily up to 85% of those exposed for over 12 months.

With equal exposure, certain TB contacts may be more likely to become infected than others. In our household contact study in Indonesia, besides those who were older, those with lower haemoglobin levels were at significantly higher risk of IGRA conversion, as were those who smoked (adjusted OR 1.47; 95% CI 0.96-2.26;

p=0.08). 3 Other factors that were rarer in our contact study, such as diabetes may also increase susceptibility to infection. 45, 46 Host genetic factors may also influence susceptibility to Mtb infection. Studies have shown higher concordance of TB disease in monozygotic twins compared to dizygotic twins, 47 robust associations with variation in several candidate genes, 48 and several loci from genome-wide association studies. [49] [50] [51] [52] [53] [54] Fewer studies have focussed explicitly on heritability and genetics of susceptibility to Mtb infection. In a study of household members with similar TB exposure, TST reactivity was correlated among siblings but not among unrelated children. 55 In a study of TST reactivity in household contacts of TB in Colombian population, a single locus accounted for 65% of TST variability. 56 In a study including 128 families in South Africa, two loci were shown to influence TST reactivity, including TST1 locus on chromosome 11p14 involved in resistance to Mtb infection, and TST2 locus on chromosome 5p15 that controlled the intensity of positive TSTs. 57 Interestingly, TST1

lies in the vicinity of the TNF1 locus that controls TNF production after stimulation by BCG and BCG plus IFNγ, and this suggested the connection between TNF production response and negative TST. 58 In another study, genome-wide linkage analysis in Uganda found regions on chromosome 2q21-2q24 (mapped to GTDC1 and ZEB2) 59 and on 5p13-5q22 (mapped to SLC6A3) 60 

Genomic variation of Mtb may also be relevant. In Indonesia, we conducted whole-genome sequencing of the Mtb isolates of the index cases, and used a SNP-based "barcode" to group the strains.

Two-fifths of the isolates were of the Beijing genotype family.

We found a significant interaction between strain and BCG vaccination with respect to IGRA test results at 14 weeks (p=0.01).

For those exposed to a non-Beijing strain, there was strong BCG protection against Mtb infection (RR 0.42; 95% CI 0.28-0.63). 62 However, for those exposed to a Beijing strain, the risk of IGRA conversion was 1.04 (95% CI 0.54-2.01), suggesting that some Mtb strains can overcome vaccine-induced, host-mediated protection.

Similarly, in a rabbit model, prior BCG vaccination did not protect against infection with the Mtb strain HN878, 63 which induces an increased pro-inflammatory response compared to other strains. 64 These findings have broad implications for understanding the epidemiology of TB in relation to BCG vaccination in populations and on the importance of testing new vaccines against multiple Mtb strains.

The immunological mechanisms of BCG-induced protection against Mtb infection are incompletely understood. BCG-mediated protection against TB has historically been attributed to vaccineinduced memory CD4 + T cells which rapidly secrete Th1 cytokines and control secondary infection with Mtb. 65 

Early clearance is defined by the absence of specific IFNγ producing T cells, making it seemingly impossible for these cells to In this section, we will briefly discuss these proposed mechanisms of early clearance.

IFNγ independent or unconventional T cell responses might play role in the early clearance mechanism. BCG re-vaccination in humans was recently shown to boost the populations of Th1-type CD4 + T cells, expressing IFNγ, IL-2, and/or TNF, as well as CD4 + T cells expressing IL-22, highlighting the importance of unbiased analyses of vaccination responses to discover previously neglected populations. 77 Th17 cells, a subset of CD4 + T cells, have been shown to confer protection against Mtb infection in murine adoptive transfer models. RAG-deficient mice, which lack both T cells and B cells,

were transferred with BCG-specific Th17 cells from immunized IFNγ-deficient mice, and these mice had a better survival rate and reduced bacterial load compared to RAG-deficient mice that received naïve T cells. 78 Another adoptive transfer study shows that transferred ESAT-6-specific Th17 CD4 + T cells partially inhibited Mtb growth. 79 

The role of antibodies in protection against Mtb is not completely understood. However, growing evidence suggests that antibodies have key contributions to protection against Mtb. 4,86-88 A study conducted in healthy, heavily exposed healthcare workers in Beijing showed that a minority of the subjects had protective antibodies against Mtb. 89 Interestingly, three out of seven subjects that pro- Mtb and other pathogens, and improves mycobacterial killing. 112, 113 When the infection cannot be cleared, the infected alveolar macrophages will eventually undergo apoptosis or necrosis. 9 Infected cells that undergo apoptosis express ATP and phosphatidylserine, which promote efferocytosis of apoptotic macrophages by uninfected monocytes and neutrophils, enhancing Mtb killing by improved delivery to the lysosomal compartment. 114 Several randomized trials in healthcare workers 134 and elderly patients that are underway or pending final analysis will provide final proof for a protective effect of BCG against COVID-19.

In search of an immunological mechanism explaining these observations, it is unlikely that cross-reactive lymphocytes are able to protect against such a broad range of pathogens. A more likely explanation of these non-specific effects is the education of the innate immune system. While it is well established that adaptive immune cells develop immunological memory upon stimulation, recent studies have shown that an infection or vaccination can also leave an imprint on innate immune cells. This de facto innate immune memory has been termed trained immunity 135, 136 and is briefly outlined in Fig. 1 . The mechanism of BCG-induced trained immunity and its possible relevance for protection against Mtb is described in more detail in the following sections.

We have conducted a series of studies to characterize the mechanisms involved in the induction of trained immunity after BCG vaccination.

PBMCs isolated from BCG-vaccinated healthy adults produce increased levels of the innate cytokines TNFα, IL-6, and IL-1β in response to stimulation with Mtb lysate, but also upon stimulation with unrelated pathogens such as Staphylococcus aureus and C. albicans. 113, [137] [138] [139] [140] [141] [142] [143] [144] [145] The elevated capacity for IL-1β and TNFα production persisted for three months post-vaccination, returning to baseline levels within 12 months. 143 After vaccination, monocytes also displayed increased surface expression of activation markers CD11b, CD14, CD206, and TLR4, and these changes persisted for 12 months. 113 

To address question whether BCG-induced trained immunity is in- LPS-induced production of pro-inflammatory cytokines. This effect was replicated in another mouse study. 129 

Several studies have helped elucidate the molecular mechanisms underlying BCG-induced trained immunity, showing that it is mediated by metabolic and epigenetic changes that affect transcription of particular genes, resulting in increased responsiveness of cells. 135, 151 This process is briefly outlined in Fig. 2 and is discussed in more depth in this section.

The altered transcriptional programme in trained immunity is me- 

The epigenetic modifications observed in BCG-induced trained immunity occur in concert with changes to intracellular metabolism, involving a metabolic shift towards glycolysis. In vitro stimulation of human monocytes with BCG leads to an increase in glucose consumption and lactate production, indicating the upregulation of glycolysis. 139, 157 H3K4me3 was increased and H3K9me3 was decreased at the promoters for key glycolysis enzymes HK2, PFKP, and the master regulator of glycolysis, mTOR, which led to increased mRNA expression of these genes. 139 Further, BCGinduced trained immunity was prevented when mTOR was inhibited by metformin treatment, indicating that increased glycolysis is essential for trained immunity.

Additionally, genes involved in glutamine metabolism, such as the glutaminolysis enzymes glutaminase and glutamate dehydrogenase, are also upregulated in monocytes after BCG training. 139 Furthermore, inhibiting glutamine metabolism, or reducing glutamine concentration in the culture medium during in vitro training, prevented the potentiation of secondary TNFα, IL-1β, and IL-6 responses. 139 Fumarate is a metabolite of glutaminolysis and has been shown to affect histone methylation and acetylation in trained immunity. Fumarate inhibits KDM5 histone demethylases enzymes (responsible for H3K4 demethylation), and stimulation of monocytes with fumarate alone resulted in increased H3K4me3 and H3K27ac, hallmark histone changes of trained immunity. 158 Accumulation of fumarate through glutaminolysis therefore links the metabolic and epigenetic changes in trained immunity. 158 Clearly, changes in intracellular metabolism are crucial for the generation of trained immunity by BCG and are intertwined with BCG-induced changes to the epigenomic landscape. only lack B and T cells. 129 Trained immunity was also induced in NK cells from BCG-vaccinated infants, as these NK cells exhibited increased expression of activation markers and secreted higher concentrations of IL-12 and IL-10 following stimulation with Pam3Cys. 147 Microbial exposure has also been shown to elicit memory-like re-

Cryptococcus neoformans produce higher levels of IFNγ, IL-2, IL-4, and TNFα following secondary challenge. 159 DCs from these vaccinated mice also express NOS2, CXCL9, and CXCL10, pro-inflammatory markers associated with M1 macrophages. These changes were linked to epigenetic changes as the effects were reduced by treatment with a methyltransferase inhibitor. Additionally, increased CXCL9 and CXCL10 production has been associated with trained immunity and enhanced anti-mycobacterial activity in a cohort of recently exposed individuals in the Netherlands. 160 Recently, it was also observed that neutrophils undergo long-term immunophenotypic changes after BCG vaccination in humans. After to those that were more permissive. 165 Additionally, the addition of GM-CSF made these macrophages more restrictive of Mtb growth, while blockage of GM-CSF made them more permissive. Further, GM-CSF production by macrophages is associated with their ability to control intracellular Mtb infection. 166 If GM-CSF is involved in BCG-induced training of myeloid precursors, this may generate differentiated macrophages with enhanced anti-mycobacterial activity and contribute to early clearance of Mtb infection.

Since early clearance has been associated with BCG vaccination, and BCG induces trained immunity, we hypothesize that BCG confers protection against Mtb infection through the induction of trained immunity. 5 This hypothesis is supported by results from a randomized trial evaluating BCG re-vaccination in South Africa. 6 BCG re-vaccination reduced the risk of sustained IGRA conversion over two years by 45.5% compared to placebo vaccination, 6 but also reduced the incidence of upper respiratory tract infections by more than 70% (2.1% in BCG re-vaccinated subjects versus 7.9% in placebo arm). This protection against heterologous, non-mycobacterial infections is a hallmark of BCG-induced trained immunity. 130 Indirect evidence may also come from our study of household contacts of TB patients in Indonesia, which has shown differences in innate immune signatures between those who were persistently IGRA negative over 14 weeks (early clearers) and IGRA converters. 167 Other immunological evidence also supports the idea that trained immunity induced by mycobacterial exposure may confer host-mediated protection against Mtb. A study of previously mycobacteria-naïve donors in the Netherlands showed that PBMCs from those who were recently exposed to Mtb had greater capacity to control the outgrowth of BCG than PBMCs from naïve controls, or from active/latent TB patients. 160 The culture supernatants of these individuals also had increased levels of TNFα, IL-1β, and IL-6, the hallmark cytokines of BCG-induced trained immunity. The increased capacity for BCG control was dependent on CXCR3 signalling and was associated with the frequency of non-classical CD14 dim monocytes which produced CXCL10. This CD14 dim monocyte population was also identified as a contracting cell population over 14 weeks among early clearers in Indonesia, suggesting a key role. 167 

In addition to studies with BCG, 150 studies with β-glucan provide strong evidence that trained immunity can protect against Mtb.

Human monocytes treated with β-glucan in vitro displayed enhanced TNFα, IL-1β, and IL-6 responses to Mtb and were more restrictive of

Mtb growth compared with naïve monocytes. 168 Intraperitoneal injection of mice with β-glucan four or seven days prior to infection with

Mtb also improved protection, reducing bacterial burden in the lung and improving survival. 168 This was mediated by shifting HSPC differentiation to myelopoiesis, increasing expression of anti-mycobacterial genes in an IL-1-dependent manner. IL-1 signalling is crucial for trained immunity, as genetic variants in this pathway modulate the induction of trained immunity by BCG, and IL-1β alone is even capable of inducing trained immunity. 140 IL-1β production has also been shown to improve anti-Mtb activity by macrophages, [169] [170] [171] intersecting trained immunity and anti-mycobacterial activity. These data suggest that the induction of trained immunity in myeloid precursors by BCG and β-glucan, mediated by cytokine signalling, may elicit improved protection against Mtb. The studies that showed the capacity of trained immunity to protect against Mtb are summarized in Table 2 . 

A number of questions remain unanswered about BCG-induced trained immunity. First, the large interindividual variability that we have observed in the induction of trained immunity after BCG vaccination has not been explained. 113, 139, 140, 152, 173 Two experimental human infection studies depicted the large interindividual variation in the ability of BCG vaccination to protect against infections, as was studied for yellow fever 139 and malaria 173 . Both studies identified "responders," people in whom BCG vaccination led to increased infection control, and "non-responders." The biological mechanism underlying this variation in BCG-induced protection is not clearly understood, and understanding this process is crucial to harness trained immunity for vaccination strategies against Mtb.

One factor that might drive the interindividual variation is host genetics, as it was shown previously that genetic variants influence cytokine responses. 174 Indeed, genetic variation related to glycolysis, autophagy, and the production of pro-inflammatory cytokines such as IL-1β influences the induction of trained immunity by BCG. 139, 140, 152 176 This result was validated by in vitro experiments using peripheral blood from healthy volunteers. Monocytes isolated in the morning had a higher capability of trained immunity compared to those isolated in the evening. This suggests that the intrinsic molecular clock of monocytes is an important regulator of BCG-induced trained immunity.

Other factors that are known to impact the immune response, including the metabolome, the gut microbiome, and immune cell subset frequencies, could also impact the magnitude of BCGinduced trained immunity responses, and could be the subject of future research.

It is not known whether different BCG strains equally induce trained immunity. Multiple strains of BCG exist, which are all subcultures of the original BCG strain, resulting in BCG vaccine heterogeneity that differ in phenotype and genotype. In terms of cytokine production after BCG vaccination, BCG-Denmark and BCG-Japan seem to be more immunogenic than other BCG strains. 177 In the context of trained immunity, studies that used BCG-Denmark 113 seem to show a higher fold-increase of cytokine after secondary stimulation with unrelated stimuli such as S. aureus, compared to studies that used BCG-Bulgaria. 144 One could hypothesize that the more immunogenic BCG strains may more robustly induce trained immunity.

It is unclear whether the route of BCG administration could influence the induction of trained immunity in humans and how this affects protection against unrelated pathogens and Mtb. Previously, intravenous BCG vaccination rather than subcutaneous BCG has been shown to induce trained immunity through imprinting of the HPSCs in mice, giving rise to macrophages which confer enhanced protection against Mtb. 150 Another recent study showed that intravenous BCG vaccination promotes better protection against TB disease compared with intradermal and aerosol BCG administration in non-human primates. 93 

We have defined delayed clearance as the elimination of Mtb infection after it has been established ( Those with active disease simultaneously have localized areas of extensive tissue pathology with bacterial growth as well as sterile granulomas. 181 The observed heterogeneity between granulomas may be a crucial determinant of the infection outcome, as the capacity for bacterial killing by individual lesions dictates the bacterial burden. 32, 182 Further, genomic barcoding of individual Mtb bacilli reveals that each granuloma in an infected host is seeded by a single organism, with considerable variation in their developmental trajectory and capacity for sterilization. 182 Rather than a globally permissive or re- 198 and the adjuvant ASO1 alone should also be examined for their capacity to induce trained immunity, and whether their capacity to do so is associated with protection against Mtb.

If markers of trained immunity show a consistent association with early clearance, this may direct future vaccine strategies to enhance the induction of trained immunity by BCG vaccination. From our studies in healthy adult volunteers, it is clear that BCG does not induce trained immunity equally well in all individuals. 113, 139, 140, 152, 153 It may be possible to modify vaccination strategies to improve the consistency with which vaccines induce trained immunity between individuals. These novel "trained immunity-based vaccines" may capitalize on innate immunological memory through the incorporation of innate immune adjuvants to already-existing vaccines such as BCG. 199 Such adjuvants that engage PRRs may amplify the trained immune response already induced by BCG, and because different stimuli induce different cell activation pathways, adjuvants may induce trained immunity pathways beyond those elicited by BCG. 200 If pathways involved in trained immunity show a consistent association with early clearance, this may direct future vaccine strategies to enhance the induction of trained immunity.

There may be ways to enhance the trained immunity effects of These "amplifiers" would be incorporated in addition to the primary immunogenic antigen or organism, and any adjuvants, ultimately enhancing effector responses and amplifying the induction of trained immunity. Cellular metabolism may be modulated by compounds analogous to metabolites of the TCA cycle, such as succinate and fumarate, leading to inhibition of KDM5 histone demethylase enzymes and improving the deposition of permissive histone marks characteristic of trained immunity. 158 Histone modifying enzymes such as HDACs, histone methyltransferases, and histone acetyltransferases may also be targeted directly to modulate the deposition and removal of histone marks and improve chromatin accessibility at the promoters of pro-inflammatory genes after vaccination. 208 Modulating the molecular mechanism of trained immunity in this way may amplify the signals induced by vaccination and improve the induction of trained immunity and further enhance protection against Mtb infection.

Essentially 

We consider three particular approaches to pre-infection trialsvaccination at birth, in adolescents, and in healthcare students.

There are other populations that are at increased risk of infection, such as people with diabetes and people living with HIV. While it will be important for a new vaccine to show efficacy in these groups, they may not be ideal groups for initial trials because they may have impaired immune responses, leading to lower, non-generalizable efficacy estimates.

Since BCG is given at birth, it would seem reasonable for new vaccines to be trialed at birth or as an early booster for BCG. In a high In their long-term follow-up of a BCG trial, Mancuso et al. 38 found that approximately 20% of TST converters in the BCG arm underwent TST reversion within five years of a positive TST, compared to less than 5% of TST converters in the placebo arm. Given that some TST conversion may be due to BCG vaccination itself, and these individuals may be expected to more readily revert, differences in IGRA reversion between arms may be smaller than differences in TST reversion.

Vaccination of adolescents is a strategy adopted in South Africa by Nemes et al. 6 A full confirmatory trial has been funded by the Bill and Melinda Gates Foundation. This is essentially a trial of BCG revaccination in a high burden/high incidence country. While the adolescents need to be IGRA negative for randomization, because of the limitations of any test for Mtb infection, and the high exposure setting, it is likely that a significant proportion have been previously 

One approach is to identify a study population transitioning into a high exposure situation. The obvious population for this is healthcare worker trainees. In Indonesia we have identified that nursing and medical students entering clinical training are such a group. They are also knowledgeable and motivated to find solutions in relation to their exposure to Mtb. In an initial study (Apriani et al., submitted for publication) we enrolled 379 students entering clinical training into a cohort study; 70 (18.5%) were IGRA positive at baseline. Of 293 IGRA negative students tested at one year, 26 (8.9%) underwent IGRA conversion. Participation in sputum collection or bronchoscopy procedures were significantly associated with IGRA conversion. We will now proceed to a proof-of-principle randomized controlled trial of BCG re-vaccination, incorporating multiple IGRA tests over a 12month follow-up period, and integrated sampling and bio-archiving for immunological studies focused on innate immune training.

It is possible to provide an estimate of the required size for a trial of a vaccine against Mtb infection in healthcare students. In the study of healthcare students, the adjusted relative risk of IGRA conversion for those who were BCG vaccinated was 0.68, with relatively wide confidence intervals in keeping with the size of the study (95% CI 0.25-1.83). Using a more stringent cutoff for conversion, there were 24 converters and the adjusted relative risk for IGRA conversion among BCG vaccinated students was 0.53 (0.19-1.53). Assuming the absolute proportion of initially IGRA negative students who are IGRA positive at 12 months is 0.09, and the proportion of students that have IGRA conversion at any time before that which converts to negative at 12 months is 0.05, the cumulative proportion of students with IGRA conversion is estimated to be 0.14 in the placebo arm. With a conservative estimate of 30% protection, the cumulative proportion of IGRA converters in the BCG intervention arm is estimated to be 0.098. Assuming 95% completion, with 1300 individuals in each arm, there would be 90% power to detect this difference at the p = 0.05 (two-sided) level of significance. If the efficacy is 40% or greater, the numbers required in each arm would be well under 1000 students.

On balance, our judgment is that there is not enough evidence that 

In intervention studies of early clearance in humans, it is essential that samples are collected before, and at various time points after intervention to capture peak responsiveness for immunological and epigenomic or transcriptomic analysis. Typically, to facilitate sample collection from a large number of individuals, responses will be measured in peripheral blood. While it must be acknowledged that peripheral blood responses do not robustly reflect the local responses in the lungs, 33 if an intervention is demonstrated to have a protective effect on infection with Mtb, peripheral blood represents a valuable, easily accessible resource to identify biomarkers that are correlated with increased protection or susceptibility to infection. Immunological assays may be performed on peripheral blood samples to assess changes in immune cell populations, cytokine responsiveness, and the capacity for mycobacterial growth inhibition.

Other assays may test for whole-blood or cell-specific transcriptomic, metabolic, and epigenomic changes. These methods allow for an evaluation of the biological response to any intervention that may correlate with susceptibility or protection against Mtb infection.

Trials in humans should be conducted in a variety of locations, particularly those where a high enough proportion of Mtb strains are of the Beijing genotype family.

The discovery that BCG is likely to protect against Mtb infection and not just progression from infection to TB disease has presented new opportunities to characterize this protection, identify associ- 

We have no conflict of interest to declare.

Philip C. Hill https://orcid.org/0000-0002-7006-0549

Variation in protection by BCG: implications of and for heterologous immunity

Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis

Early clearance of Mycobacterium tuberculosis: the INFECT case contact cohort study in Indonesia

IFN-γ-independent immune markers of Mycobacterium tuberculosis exposure

Trained innate immunity and resistance to Mycobacterium tuberculosis infection

Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination

TB or not TB: that is no longer the question

Eliminating latent tuberculosis

Early clearance of Mycobacterium tuberculosis: a new frontier in prevention

A study of tuberculosis among students of nursing

The epidemiology of tuberculosis infection in a closed environment

Resistance and susceptibility to Mycobacterium tuberculosis infection and disease in tuberculosis households in Kampala, Uganda

Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis

The prognosis of a positive tuberculin reaction in childhood and adolescence

Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection

The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection

Tuberculosis case-contact research in endemic tropical settings: design, conduct, and relevance to other infectious diseases

Four-gene pan-African blood signature predicts progression to tuberculosis

A blood RNA signature for tuberculosis disease risk: a prospective cohort study

Discovery and validation of a prognostic proteomic signature for tuberculosis progression: a prospective cohort study

Is Mycobacterium tuberculosis infection life long?

Distribution of tuberculous infection and disease among households in a rural community

Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection

Epidemiology of tuberculosis

Epidemiological basis of tuberculosis eradication. 10. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area

Evidence for waning of latency in a cohort study of tuberculosis

Tuberculosis in Siberia: 1. An epidemiological and microbiological assessment

Tuberculous infection: attempts to prevent it by subcutaneous vaccination with BCG

Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial

Effect of isoniazid preventive therapy on immune responses to Mycobacterium tuberculosis: an open label randomised, controlled, exploratory study

Radiologic responses in cynomolgus macaques for assessing tuberculosis chemotherapy regimens

Digitally barcoding Mycobacterium tuberculosis reveals in vivo infection dynamics in the macaque model of tuberculosis

Variability in tuberculosis granuloma T cell responses exists, but a balance of pro-and anti-inflammatory cytokines is associated with sterilization

The potential of imaging tools as correlates of infection and disease for new TB vaccine development

Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure

Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study

Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study

The long-term effect of Bacille Calmette-Guérin vaccination on tuberculin skin testing: a 55-year follow-up study

The role of BCG in prevention of leprosy: a meta-analysis

Does the efficacy of BCG decline with time since vaccination?

The duration of protection of school-aged BCG vaccination in England: a population-based case-control study

Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study

BCG protection against Mycobacterium tuberculosis infection by level of exposure in The Gambia

A study of tuberculous infection and mortality in the children of tuberculous households

Latent TB infection and pulmonary TB disease among patients with diabetes mellitus in Bandung

Diabetes mellitus and latent tuberculosis infection: a systematic review and metaanalysis

Tuberculosis in twins: a re-analysis of the Prophit survey

Genomics of human pulmonary tuberculosis: from genes to pathways

Genome-wide association study of ancestry-specific TB risk in the South African coloured population

Susceptibility to tuberculosis is associated with variants in the ASAP1 gene encoding a regulator of dendritic cell migration

A locus at 5q33.3 confers resistance to tuberculosis in highly susceptible individuals

Genome scan of M. tuberculosis infection and disease in Ugandans

Common variants at 11p13 are associated with susceptibility to tuberculosis

Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2

Evaluation of tuberculin reactivity in BCG-immunized siblings

Tuberculin skin test reactivity is dependent on host genetic background in Colombian tuberculosis household contacts

Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis

Identification of a major locus, TNF1, that controls BCG-triggered tumor necrosis factor production by leukocytes in an area hyperendemic for tuberculosis

Fine-mapping analysis of a chromosome 2 region linked to resistance to mycobacterium tuberculosis infection in Uganda reveals potential regulatory variants

Polymorphisms in TICAM2 and IL1B are associated with TB

HLA class II sequence variants influence tuberculosis risk in populations of European ancestry

Lower Bacillus Calmette-Guérin protection against Mycobacterium tuberculosis infection after exposure to Beijing strains

Inoculum size and traits of the infecting clinical strain define the protection level against Mycobacterium tuberculosis infection in a rabbit model

BCG vaccination of infants confers Mycobacterium tuberculosis strain-specific immune responses by leukocytes

Moving tuberculosis vaccines from theory to practice

Beyond memory T cells: mechanisms of protective immunity to tuberculosis infection

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebocontrolled, phase 2 trial

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

The recombinant Bacille Calmette-Guérin vaccine VPM1002: ready for clinical efficacy testing

Safety and immunogenicity of the recombinant BCG vaccine VPM10002 in a phase 1 open-label randomized clinical trial

Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa

Construction, characterization and preclinical evaluation of MTBVAC, the first liveattenuated M. tuberculosis-based vaccine to enter clinical trials

Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind doseescalation trial

Phase 2b controlled trial of M72/AS01 E vaccine to prevent tuberculosis

Tuberculosis vaccine development: progress in clinical evaluation

The status of tuberculosis vaccine development

Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines

Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon

A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo

An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment

MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis

Mucosal-associated invariant T cells develop an innate-like transcriptomic program in antimycobacterial responses

γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection

Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes

Mucosal-associated invariant and γδ T cell subsets respond to initial Mycobacterium tuberculosis infection

A case for antibodies as mechanistic correlates of immunity in tuberculosis

A functional role for antibodies in tuberculosis

Antibody Fc glycosylation discriminates between latent and active tuberculosis

Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis

An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. tuberculosis specific antibodies in Cape Town

Fcgamma receptors as regulators of immune responses

Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection

Prevention of tuberculosis in macaques after intravenous BCG immunization

In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans

Thinking outside the box: innate-and B cell-memory responses as novel protective mechanisms against tuberculosis

Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis

Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo

Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection-the double-edged sword?

Van Crevel R. Innate immune recognition of Mycobacterium tuberculosis

The macrophage: a disputed fortress in the battle against Mycobacterium tuberculosis

Toll-like receptor-2 mediates mycobacteria-induced pro-inflammatory signaling in macrophages

Transcriptional and inflammasome-mediated pathways for the induction of IL-1beta production by Mycobacterium tuberculosis

Mycobacterium tuberculosis heat shock proteins use diverse toll-like receptor pathways to activate pro-inflammatory signals

Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice

TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis

IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection

Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88

Cutting edge: toll-like receptor (TLR)2-and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis

NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis

Mycobacterium paratuberculosis is recognized by toll-like receptors and NOD2

NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages

Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes

Efferocytosis is an innate antibacterial mechanism

Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy?

Chemokines in tuberculosis: the good, the bad and the ugly

Rat neutrophils prevent the development of tuberculosis

Neutrophils play a protective nonphagocytic role in systemic Mycobacterium tuberculosis infection of mice

The immune response in tuberculosis

Neutrophilmediated innate immune resistance to mycobacteria

Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens

Differential effect of viable versus necrotic neutrophils on Mycobacterium tuberculosis growth and cytokine induction in whole blood

IL-17 production from T helper 17, mucosal-associated invariant T, and γδ cells in tuberculosis infection and disease

Human natural killer cells mediate killing of intracellular Mycobacterium tuberculosis H37Rv via granule-independent mechanisms

Control of Mycobacterium tuberculosis growth by activated natural killer cells

Mechanisms of natural killer cell-mediated cellular cytotoxicity

NK cells kill mycobacteria directly by releasing perforin and granulysin

Adaptive immune features of natural killer cells

BCG-induced trained immunity in NK cells: role for non-specific protection to infection

Non-specific effects of vaccines: current evidence and potential implications

BCG-induced trained immunity: can it offer protection against COVID-19?

BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)

BCG vaccination early in life does not improve COVID-19 outcome of elderly populations, based on nationally reported data

BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: a structured summary of a study protocol for a randomised controlled trial

Defining trained immunity and its role in health and disease

Trained immunity: a memory for innate host defense

Long-term in vitro and in vivo effects of γ-irradiated BCG on innate and adaptive immunity

Vitamin A induces inhibitory histone methylation modifications and downregulates trained immunity in human monocytes

Immunometabolic pathways in BCG-induced trained immunity

BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity

BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment

Activate: randomized clinical trial of BCG vaccination against infection in the elderly

Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity

BCG vaccination in humans inhibits systemic inflammation in a sex-dependent manner

BCG-induced trained immunity in healthy individuals: the effect of plasma muramyl dipeptide concentrations

Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-controlled trial

Whole blood profiling of Bacillus Calmette-Guérin-induced trained innate immunity in infants identifies epidermal growth factor, IL-6, plateletderived growth factor-AB/BB, and natural killer cell activation

Neonatal BCG vaccination reduces interferon-γ responsiveness to heterologous pathogens in infants from a randomized controlled trial

Increased NOD2-mediated recognition of n-glycolyl muramyl dipeptide

BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis

Epigenetics and trained immunity

Autophagy controls BCGinduced trained immunity and the response to intravesical BCG therapy for bladder cancer

Anti-mycobacterial activity correlates with altered DNA methylation pattern in immune cells from BCG-vaccinated subjects

Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination

The intersection of epigenetics and metabolism in trained immunity

Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments

In vitro experimental model of trained innate immunity in human primary monocytes

Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity

Induction of memorylike dendritic cell responses in vivo

Mycobacterial growth inhibition is associated with trained innate immunity

BCG vaccination induces long-term functional reprogramming of human neutrophils

The fate and lifespan of human monocyte subsets in steady state and systemic inflammation

Modulation of myelopoiesis progenitors is an integral component of trained immunity

Molecular analysis of a short-term model of β-glucans-trained immunity highlights the accessory contribution of GM-CSF in priming mouse macrophages response

Heterogeneous gm-csf signaling in macrophages is associated with control of Mycobacterium tuberculosis

GM-CSF dependent differential control of Mycobacterium tuberculosis infection in human and mouse macrophages: is macrophage source of GM-CSF critical to tuberculosis immunity?

Early clearance of Mycobacterium tuberculosis is associated with increased innate immune responses

β-glucan induces protective trained immunity against Mycobacterium tuberculosis infection: a key role for IL-1

Human gene variants linked to enhanced NLRP3 activity limit intramacrophage growth of Mycobacterium tuberculosis

Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome

Human macrophages infected with a high burden of ESAT-6-expressing M. tuberculosis undergo caspase-1-and cathepsin B-independent necrosis

tuberculosis reprograms hematopoietic stem cells to limit myelopoiesis and impair trained immunity

Outcomes of controlled human malaria infection after BCG vaccination

A functional genomics approach to understand variation in cytokine production in humans

Identification of DNA methylation patterns predisposing for an efficient response to BCG vaccination in healthy BCG-naïve subjects

Circadian rhythm influences induction of trained immunity by BCG vaccination

Early vaccination with Bacille Calmette-Guérin-Denmark or BCG-Japan versus BCG-Russia to healthy newborns in Guinea-Bissau: a randomized controlled trial

Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia

Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guérin

Bacillus Calmette-Guérin-induced trained immunity is not protective for experimental influenza A/Anhui/1/2013 (H7N9) infection in mice

Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model

Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing

Host transcriptional response to TB preventive therapy differentiates two sub-groups of IGRA-positive individuals

Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection

Inhibiting histone deacetylases in human macrophages promotes glycolysis, IL-1β, and T helper cell responses to Mycobacterium tuberculosis

Functional inhibition of host histone deacetylases (HDACs) enhances in vitro and in vivo anti-mycobacterial activity in human macrophages and in zebrafish

Identification of host proteins predictive of early stage Mycobacterium tuberculosis infection

Immunometabolic signatures predict risk of progression to active tuberculosis and disease outcome

Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study

Metabolite changes in blood predict the onset of tuberculosis

Active and prospective latent tuberculosis are associated with different metabolomic profiles: clinical potential for the identification of rapid and non-invasive biomarkers

Understanding human immune function using the resources from the human functional genomics project

A genome-wide functional genomics approach identifies susceptibility pathways to fungal bloodstream infection in humans

Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans

MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice

Revaccination of guinea pigs with the live attenuated Mycobacterium tuberculosis vaccine MTBVAC improves BCG's protection against tuberculosis

New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia

Final analysis of a trial of M72/AS01 E vaccine to prevent tuberculosis

Trained immunitybased vaccines: a new paradigm for the development of broadspectrum anti-infectious formulations

BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny

Th1 cytokine-secreting recombinant mycobacterium bovis Bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

Interferon-gamma improves macrophages function against M. tuberculosis in multidrug-resistant tuberculosis patients

Mycobacterium tuberculosis exploits human interferon-γ to stimulate macrophage extracellular trap formation and necrosis

Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection

Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs

Investigation of immunogenic effect of the BCG priming and Ag85A-GM-CSF boosting in Balb/c mice model

Epigenetic regulation of the innate immune response to infection

BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next-generation vaccines